Imprinting disorders are a group of rare conditions that arise when genes meant to be active from only one parent’s copy are silenced, duplicated, or otherwise disrupted. During normal development, certain stretches of DNA are chemically tagged so that only the mother’s or the father’s version gets switched on in a child’s cells. When that tagging goes wrong, the result can range from severe growth abnormalities and intellectual disability to neonatal diabetes and hormone resistance. At least a dozen recognized syndromes fall under the imprinting-disorder umbrella, and the underlying causes span outright chromosomal deletions, inheritance of both copies from one parent, and subtler chemical changes to DNA that leave the sequence itself intact.
How Genomic Imprinting Sets the Stage
Most genes come in two working copies, one inherited from each parent, and either copy can do the job. Imprinted genes are different. During egg and sperm formation, specific regions of DNA pick up chemical marks, mainly methyl groups, that silence one parental copy while leaving the other active. Which copy stays on depends on whether it came through the egg or the sperm. The result is parent-specific expression: for some genes, only the father’s copy works; for others, only the mother’s copy does.1PubMed Central. Epigenetic mechanisms of genomic imprinting: common themes in the regulation of imprinted regions in mammals, plants, and insects This arrangement means there is no backup. If the one active copy is lost or silenced, the cell has zero working copies, and a disorder can follow.
One evolutionary explanation for why imprinting exists at all is the genetic conflict hypothesis. The idea is that a father’s genes “want” to extract as many resources from the mother as possible to benefit his offspring, while the mother’s genes “want” to ration resources across all her children. Paternally expressed genes therefore tend to promote growth, and maternally expressed genes tend to restrain it.2PubMed. The conflict theory of genomic imprinting: how much can be explained? That tug-of-war helps explain why many imprinting disorders show up as either overgrowth or undergrowth.
Prader-Willi and Angelman Syndromes
The best-known pair of imprinting disorders involves the same stretch of chromosome 15, region 15q11-q13. When the father’s copy of this region is missing or silent, the result is Prader-Willi syndrome (PWS), characterized by low muscle tone in infancy, an insatiable appetite that develops in early childhood, intellectual disability, and short stature. When the mother’s copy is disrupted instead, the result is Angelman syndrome (AS), which features severe developmental delay, absent or very limited speech, seizures, and a characteristically happy demeanor with frequent laughter.3PubMed Central. Prader-Willi and Angelman Syndromes: Mechanisms and Management
The most common cause of both syndromes is a large deletion in the 15q11-q13 region, but the parent of origin determines which syndrome appears. Deletions in PWS patients are predominantly paternal in origin, while Angelman-associated deletions come from the maternal chromosome. Angelman deletions also tend to be somewhat larger and more variable, sometimes extending into adjacent bands.4PubMed. Comparison of the 15q deletions in Prader-Willi and Angelman syndromes: specific regions, extent of deletions, parental origin, and clinical consequences The fact that the same chromosomal neighborhood produces two completely different syndromes depending on which parent’s copy is lost is what first drew widespread attention to genomic imprinting in the late 1980s.
Growth Disorders on Chromosome 11
Beckwith-Wiedemann syndrome (BWS) is an overgrowth condition that can present with a large tongue (macroglossia), abdominal wall defects, low blood sugar in newborns, and an elevated risk of childhood tumors, especially Wilms tumor and hepatoblastoma.5PubMed Central. Diagnosis and Management of Beckwith-Wiedemann Syndrome BWS traces to region 11p15, which houses two imprinting control centers. The balance between paternally expressed growth-promoting genes and maternally expressed growth-suppressing genes can tip in several ways: loss of methylation at imprinting center 2 on the maternal chromosome, gain of methylation at imprinting center 1 on the maternal chromosome, paternal uniparental disomy of chromosome 11 (where both copies come from the father), or a mutation in the maternal copy of the growth-suppressor gene CDKN1C.6Fertility and Sterility. Beckwith-Wiedemann syndrome
Silver-Russell syndrome (SRS) sits at the opposite end of the growth spectrum. Children with SRS are small at birth despite a normal-length pregnancy, grow slowly after birth, and often have a triangular face and body asymmetry. The molecular picture was murky for years, but research eventually linked most cases to imprinted genes on chromosomes 7 and 11p15, the same region involved in BWS but with the balance shifted in the opposite direction.7PubMed. Epigenetics in Silver-Russell syndrome Where BWS reflects too much growth-gene activity, SRS often reflects too little.
Imprinting Disorders on Chromosome 14
Temple syndrome (TS) and Kagami-Ogata syndrome (KOS) mirror each other on chromosome 14q32, much as PWS and AS do on chromosome 15. Temple syndrome typically arises from maternal uniparental disomy of chromosome 14 or from epigenetic changes that silence paternally expressed genes in the 14q32 cluster. Features include prenatal and postnatal growth restriction, early puberty, and mild intellectual disability. Kagami-Ogata syndrome, by contrast, arises from paternal uniparental disomy of chromosome 14 or from silencing of maternally expressed genes, and produces a distinctive pattern of skeletal abnormalities, a bell-shaped thorax, and placental overgrowth.8PubMed Central. Temple syndrome and Kagami-Ogata syndrome: clinical presentations, genotypes, models and mechanisms
A key gene in this cluster is RTL1, which is expressed from the paternal copy. Mouse studies show that both overexpression and underexpression of RTL1 cause reduced movement, increased anxiety, and problems with fear learning, suggesting that RTL1 dosage affects the brain as well as muscle and placental tissue.9PubMed Central. The role of eutherian-specific RTL1 in the nervous system and its implications for the Kagami-Ogata and Temple syndromes These findings reframe both syndromes as neuromuscular and neuropsychiatric conditions, not just growth-related ones.
Endocrine Imprinting Disorders
Not all imprinting disorders center on growth or neurodevelopment. Transient neonatal diabetes mellitus (TNDM) is a rare condition in which a newborn develops uncontrolled high blood sugar in the first weeks or months of life, typically resolving by about six months, though diabetes can recur later. The cause is overexpression of paternally expressed genes at the 6q24 locus, which can happen through paternal uniparental disomy of chromosome 6, a paternally inherited duplication of 6q24, or a methylation defect at a regulatory island overlapping those genes.10PubMed Central. Transient neonatal diabetes, a disorder of imprinting Some patients also carry mutations in ZFP57, a gene that helps maintain methylation marks across multiple imprinted sites, which can produce broader imprinting disturbance alongside the diabetes.11PubMed. Transient neonatal diabetes mellitus and hypomethylation at additional imprinted loci: novel ZFP57 mutation and review on the literature
Pseudohypoparathyroidism (PHP) is another endocrine example, involving the GNAS locus on chromosome 20. GNAS encodes a signaling protein called Gsα that is needed for cells to respond to parathyroid hormone and several other hormones. Because Gsα is imprinted in certain tissues (primarily the kidneys and thyroid), the parent of origin of a GNAS mutation determines the clinical picture. A maternally inherited inactivating mutation causes PHP type 1a, characterized by hormone resistance plus a set of skeletal features known as Albright hereditary osteodystrophy. The same mutation inherited from the father leads to the skeletal features alone, without hormone resistance, in a condition called pseudopseudohypoparathyroidism, or in severe cases to progressive osseous heteroplasia, a condition of deep bone formation in soft tissues.12PubMed Central. GNAS mutations in Pseudohypoparathyroidism type 1a and related disorders
A related but distinct subtype, PHP type 1b, results not from coding mutations in GNAS but from methylation changes at regulatory regions upstream of the gene. These epigenetic changes can be caused by maternal deletions in the nearby STX16 gene, chromosomal duplications, retrotransposon insertions, or inversions that scramble the region’s architecture.13The Journal of Clinical Endocrinology & Metabolism. Molecular Definition of Pseudohypoparathyroidism Variants – Section: The GNAS Complex Locus Gives Rise to Different Variants of Gsα and to Several Additional Transcripts Recent work has shown that methylation levels at a specific probe near the GNAS locus can help narrow down which genetic defect is responsible in individual patients, which could speed diagnosis.14The Journal of Clinical Investigation. GNAS AS2 methylation status enables mechanism-based categorization of pseudohypoparathyroidism type 1B
What Goes Wrong at the Molecular Level
The causes of imprinting disorders fall into a few broad categories. The first is chromosomal deletion: a chunk of DNA that includes the active copy of an imprinted gene is physically lost. This is the most common mechanism in both PWS and AS. The second is uniparental disomy (UPD), where a child inherits both copies of a chromosome (or part of one) from the same parent. If both copies come from the mother, any genes that are supposed to be active only from the father are effectively absent, and vice versa.
UPD most often arises through a process called trisomy rescue. An error during egg or sperm formation leaves a fertilized embryo with three copies of a chromosome instead of two. To survive, the embryo’s cells eliminate the extra copy. If the copy that gets discarded happens to be the lone one from the other parent, the child ends up with two copies from a single parent.15PubMed Central. Trisomy rescue mechanism: the case of concomitant mosaic trisomy 14 and maternal uniparental disomy 14 in a 15‐year‐old girl Two other, less common routes can produce UPD: gamete complementation, where both the egg and sperm happen to carry complementary errors so that the embryo starts with the right total count but from one parent, and monosomy rescue, where the embryo starts with only one copy and duplicates it.16OBM Genetics. Uniparental Disomy and Imprinting Disorders – Section: Mechanisms of Whole Chromosome UPD Formation
The third major cause is an epimutation: the DNA sequence is normal, but the methylation marks that should be silencing one copy are gained or lost inappropriately. This is the predominant mechanism in BWS cases driven by loss of methylation at imprinting center 2, and it is common in SRS and TNDM as well. Because epimutations leave the DNA code intact, they can be harder to detect and are not always inherited in a straightforward way.
Multilocus Imprinting Disturbance
Most imprinting disorders affect a single chromosomal region. But in a subset of patients, methylation is disrupted at multiple imprinted sites scattered across different chromosomes, a pattern called multilocus imprinting disturbance (MLID). A patient might present with BWS, for instance, yet also show abnormal methylation at loci on chromosomes 6, 7, and 15.17PubMed. Clinical and molecular genetic features of Beckwith-Wiedemann syndrome associated with assisted reproductive technologies The clinical picture in MLID cases can be atypical, with features that do not fit neatly into a single recognized syndrome.
Research into what drives MLID has pointed to mutations in genes active in the mother’s egg cells, particularly NLRP2, NLRP7, and PADI6. These “maternal effect” proteins help establish and protect the methylation marks laid down before and just after fertilization. Mothers of children with MLID carry a statistically significant excess of coding variants in these genes.18Journal of Medical Genetics. Maternal variants in NLRP and other maternal effect proteins are associated with multilocus imprinting disturbance in offspring Because the mutations sit in the mother’s genome rather than the child’s, MLID has an unusual inheritance pattern: the mother is healthy, but her eggs may fail to set imprints correctly in some or all of her pregnancies.
Assisted Reproductive Technology and Imprinting Risk
Animal studies first raised the concern that procedures involved in assisted reproduction, especially in vitro fertilization and embryo culture, might alter DNA methylation patterns at imprinted loci.19PubMed Central. Imprinting disorders and assisted reproductive technology Human data have since accumulated. A large Swedish registry study found that children conceived through assisted reproductive technology (ART) had a roughly 50 percent higher rate of diagnosed imprinting disorders compared with children of couples with known infertility who conceived without ART. The risk was not evenly distributed across procedures: the combination of intracytoplasmic sperm injection and frozen embryo transfer was associated with a much sharper increase in risk for both PWS/SRS and BWS individually.20Fertility and Sterility. Imprinting disorders in children conceived with assisted reproductive technology in Sweden
It remains genuinely difficult to untangle how much of this elevated risk comes from the ART procedures themselves versus from the underlying infertility that led couples to seek treatment. Some of the statistical association weakens after adjusting for parental background factors. Still, the biological plausibility is strong: the critical window for establishing methylation imprints in eggs and early embryos overlaps directly with the time period when ART manipulations take place. Among BWS patients conceived via ART, loss of maternal methylation at imprinting control regions beyond the 11p15 locus, a marker of more generalized imprinting disruption, was found in about a third of ART cases compared with a small fraction of non-ART cases.17PubMed. Clinical and molecular genetic features of Beckwith-Wiedemann syndrome associated with assisted reproductive technologies The absolute risk remains very small for any individual pregnancy, but the relative increase is enough that some clinicians recommend heightened awareness when ART-conceived children show possible signs of an imprinting disorder.
How Imprinting Disorders Are Diagnosed
Suspicion usually starts with clinical features: the hypotonia and feeding difficulty of a PWS infant, the large tongue and abdominal wall defect in a newborn with possible BWS, or unexplained neonatal diabetes. From there, the diagnostic workup depends on the suspected syndrome, but a few testing strategies cover most of the ground.
Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) has become a workhorse first-line test for several imprinting disorders. For PWS and AS, it can simultaneously detect abnormal methylation patterns and determine whether a deletion is present, making it more informative than older methylation-only tests.21PubMed Central. Clinical Utility of Methylation-Specific Multiplex Ligation-Dependent Probe Amplification for the Diagnosis of Prader-Willi Syndrome and Angelman Syndrome The same technique works for the 11p15 region, where it can distinguish between the different epigenetic and copy-number changes that cause BWS and SRS.22PubMed. Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) robustly detects and distinguishes 11p15 abnormalities associated with overgrowth and growth retardation
When UPD is suspected, or when the clinical picture does not fit a single syndrome cleanly, genome-wide SNP microarray analysis offers a broader view. By comparing the child’s two copies of each chromosome, the array can spot deletions, duplications, and stretches of DNA where both copies look like they came from the same parent, flagging possible UPD. In one study, SNP array identified deletions, mosaic UPD, and large-scale UPD events across chromosomes 11, 14, and 15 in patients with suspected imprinting disorders, though it occasionally missed smaller regions that required additional testing to confirm.23Cytogenetic and Genome Research. Rapid Diagnosis of Imprinting Disorders Involving Copy Number Variation and Uniparental Disomy Using Genome-Wide SNP Microarrays No single test catches every mechanism, so a stepwise approach, sometimes starting with MS-MLPA and moving to microarray or targeted sequencing, is typical in clinical practice.
Tumor Surveillance in Beckwith-Wiedemann Syndrome
Children with BWS face an elevated risk of embryonal tumors, but the level of risk depends heavily on which molecular subtype is responsible. Patients with gain of methylation at imprinting center 1 or paternal UPD carry the highest risk of Wilms tumor and may also be at risk for hepatoblastoma and adrenal tumors. By contrast, patients with loss of methylation at imprinting center 2, the most common BWS subtype, have a much lower overall tumor risk.24PubMed. Cancer Risk in Beckwith-Wiedemann Syndrome: A Systematic Review and Meta-Analysis Outlining a Novel (Epi)Genotype Specific Histotype Targeted Screening Protocol These differences have led multiple expert groups to propose differentiated screening protocols: frequent renal ultrasounds and blood alpha-fetoprotein monitoring for high-risk subtypes, and potentially relaxed surveillance for the lower-risk loss-of-methylation group.25PubMed. Phenotype, cancer risk, and surveillance in Beckwith-Wiedemann syndrome depending on molecular genetic subgroups Getting the molecular diagnosis right early is therefore not just academic; it shapes which screenings a child undergoes for the first several years of life.26PubMed Central. Tumor screening in Beckwith-Wiedemann syndrome-To screen or not to screen?
Emerging Therapies for Angelman Syndrome
For most imprinting disorders, treatment remains supportive: growth hormone for short stature, dietary management for PWS, seizure medications for AS, and so on. But Angelman syndrome has become a proving ground for a more direct approach. The key gene in AS, UBE3A, is silenced on the paternal chromosome in neurons by a long antisense RNA transcript. In principle, if you could shut down that antisense transcript, the normally silent paternal copy of UBE3A would wake up and compensate for the missing maternal copy.
Antisense oligonucleotides (ASOs) designed to degrade the silencing transcript have shown striking results in mouse models of AS. A single injection into the brain of newborn or young mice restored UBE3A protein to up to about three-quarters of normal levels in the cortex and fully rescued seizure susceptibility.27PubMed Central. Antisense oligonucleotide treatment rescues UBE3A expression and multiple phenotypes of an Angelman syndrome mouse model In a separate mouse model that specifically recapitulates the imprinting-defect subtype of AS, genetic overexpression of UBE3A completely rescued all behavioral and proteomic abnormalities, and ASO treatment achieved partial behavioral rescue while raising UBE3A to about 30 percent above wild-type levels.28PubMed Central. UBE3A reinstatement restores behavior and proteome in an Angelman syndrome mouse model of imprinting defects
Researchers have even tested prenatal delivery, hypothesizing that the earlier the intervention, the greater the benefit. Prenatal ASO injections in pregnant mice led to increased UBE3A in the offspring’s brains and functional improvements after birth.29Molecular Therapy. Prenatal antisense oligonucleotide therapy rescues Angelman syndrome in mice Clinical trials in humans are ongoing, and the early mouse data have generated real excitement, though the leap from rodent models to lasting benefit in people remains uncertain. The broader significance is that it demonstrates the logic that could extend to other imprinting disorders: if the silenced copy of a gene is structurally intact, there may be ways to reactivate it.
Folate, Pregnancy, and Imprinted Gene Methylation
Given that imprinting depends on methylation, and that folate is central to the body’s methylation chemistry, a natural question is whether a mother’s folate intake during pregnancy affects imprinting in the child. One study found that folic acid supplement use in the first twelve weeks of pregnancy had no detectable effect on imprinted gene methylation in offspring. However, continued supplementation after twelve weeks was associated with small but measurable changes: slightly higher methylation at the growth-related gene IGF2 and slightly lower methylation at PEG3, another imprinted gene. The same pattern tracked with folate levels measured in cord blood at birth.30The American Journal of Clinical Nutrition. Folate in pregnancy and imprinted gene and repeat element methylation in the offspring
These methylation shifts were subtle, and the study did not link them to clinical imprinting disorders. Still, the findings illustrate that imprinting marks are not entirely fixed at conception. Environmental exposures during pregnancy can nudge methylation levels at imprinted loci, even if those nudges are normally too small to cause disease. Whether extreme nutritional deficiencies or environmental toxins could push those shifts past a clinically meaningful threshold is an area of active investigation, but there is no evidence that standard prenatal vitamin use causes imprinting disorders.